Connect with us

BIOTECH

InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) Releases Year End Review

Published

on

InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) released yearend review for FY2016. Eric A. Adams, the President and CEO said that they want to express their thanks to all of their shareholders for their continued support of company as they establish a firm in what they consider is the most thrilling biotech segment in the present time, and that is cannabinoid-based drug advancement.

The details

Throughout this year, the scientific focus has been on towards validating drug candidate selection, utilizing data to secure patents and further advance major disruptive technologies. In the last 12-months, InMed added strong biopharmaceutical expertise to management and its Board of Directors. It raised capital to support continued drug/disease target discovery using proprietary bioinformatics analysis tool.

There was strong analysis of current datasets to ensure that clinical development plans are precise and positioned to take full advantage of the probability for positive outcomes. The advancement and validation of the biosynthesis manufacturing procedure; submission of provisional patents to commercially guard this main invention. Another achievement recorded in this year was expanded scope of prospects for cannabinoid-based medications by validating new disease/drug targets in in-vitro and in-vivo efficacy model

InMed has been successful in attracting extensively experienced and highly qualified pharmaceutical and biotech professionals to both the Board of Directors and Management Team in 2016. Alex Mancini, the Senior VP of Clinical and Regulatory Affairs, has been instrumental in strengthening the INM-750 development plan for epidermolysis bullosa and will persist to direct their initiatives mainly towards closing on this program.

Dr. Bill Garner, the Chairman of the Board, has offered valuable leadership and performed major introductions on behalf of the firm for strategic development and financings. Mr. Andrew Hull, the Director has carried out a detailed assessment of the science and designation of drug development plans to help know prospective pathways towards associations for their many assets. InMed mentioned the recent addition, Jeff Charpentier as CFO, is a veteran of the biopharmaceutical industry and will offer valuable leadership in financial aspects of their firm.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.